Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEBO versus povidone iodine plus bepanthenol for moderate burns in Greece
ISRCTN74058791Phase 4Completed
- Sponsor
- G. Gennimatas General Hospital
- Start
- Jan 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of MEBO, povidone-iodine and dexpanthenol in burn injury (2 arms), sponsored by G. Gennimatas General Hospital. Primary endpoints: Mean reduction in days of in-hospital stay and Time of recovery for superficial partial thickness burns by TEWL. Started Jan 2002; status: completed.
02
Drugs
MEBOpovidone-iodinedexpanthenol
03
Conditions
burn injury
Beyond the preview
Go deeper on ISRCTN74058791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN74058791.